Safyhr Award
This award has been made possible with an unrestricted grant from Sanofi to support Young Hematologist Researcher.
The call for applications for the Safyhr Award 2025 is now CLOSED.
Young hematologists and pediatric hemato-oncologists in training are invited to submit their project and apply for the Sanofi Award for Young Hematologist Researcher.
The “Safyhr Award” jury will select only one innovative project that will be awarded with 15.000 EUR.
The award ceremony will take place during 40th BHS general annual meeting on February 7-8, 2025.
Discover the past SAFYHR AWARD winners down below!
Sincerely,
Prof. Marc André, President of the BHS
Participation requirements
The application must preferably be written in English** and must consist of :
- Description of the research project including costs and time frame (max. 2 pages) Detailed project form Safyhr Award 2025
- Letter of support by a promoter from the department where the research will be performed (max. 1 page)
- Motivational letter (max 1 page)
- List of publications (if applicable)
- CV
** applications in French or Dutch are acceptable, but the abstract/summary must be in English
Who can apply?
The candidate must fulfill all criteria below:
- Young hematologists and pediatric hemato-oncologists in training who are MD and are within 10 years after MD graduation.
- Young researchers (PhD student) with a hematologist as their promoter or co-promoter
Important note: Candidates working at a pharmaceutical company are excluded.
Which projects are eligible?
The topic of research is related to transnational research within the field of hematology.
IMPORTANT NOTE: Please be informed non-selected projects from previous years may be resubmitted if they meet the eligibility criteria.
Past winners
2025
| Name | Organisation | Project title |
Eleni Linskens | UZ Brussels | Detection of FLT3-ITD measurable residual disease (MRD) in FLT3-ITD positive AML patients by sequencing-based assays |
2024
| Name | Organisation | Project title |
Gaël Vermeersch | UZ Leuven/ KU Leuven/ Rega Institute | Bone marrow neutrophilic granulocytes as therapeutic targets in primary myelofibrosis |
2023
| Name | Organisation | Project title |
| Quentin Van Thillo | KU Leuven | Targeting NOTCH1/2-positive diffuse large B-cell lymphoma (DLBCL) with presenilin 1-selective gamma-secretase inhibitors |
2022
| Philippe Decruynaere | Ghent University Hospital | Nucleic acid profiling in diffuse large B-cell lymphoma: a molecular guidance to precision medicine |
2021
| Willem Daneels | Ghent University Hospital | The development of advanced humanized patient-derived tumor xenograft models of lymphoproliferative malignancies for the evaluation of novel therapeutics |